Phapros Tbk PT - Asset Resilience Ratio
Phapros Tbk PT (PEHA) has an Asset Resilience Ratio of 5.12% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2011–2025)
This chart shows how Phapros Tbk PT's Asset Resilience Ratio has changed over time. Check asset allocation strategy of Phapros Tbk PT to assess the company's strategic physical and investment asset allocation.
Liquid Assets Composition Over Time
This chart breaks down Phapros Tbk PT's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Phapros Tbk PT stock valuation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Rp70.40 Billion | 5.08% |
| Short-term Investments | Rp620.61 Million | 0.04% |
| Total Liquid Assets | Rp71.02 Billion | 5.12% |
Asset Resilience Insights
- Limited Liquidity: Phapros Tbk PT maintains only 5.12% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
Phapros Tbk PT Industry Peers by Asset Resilience Ratio
Compare Phapros Tbk PT's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
ST:SOBI |
Drug Manufacturers - Specialty & Generic | 1.54% |
|
Alkem Laboratories Limited
NSE:ALKEM |
Drug Manufacturers - Specialty & Generic | 31.91% |
|
Shan Dong Dong-E E-Jiao Co Ltd
SHE:000423 |
Drug Manufacturers - Specialty & Generic | 20.44% |
|
Alkermes plc
F:8AK |
Drug Manufacturers - Specialty & Generic | 3.76% |
|
Jilin Aodong Pharmaceutical Group Co Ltd
SHE:000623 |
Drug Manufacturers - Specialty & Generic | 4.97% |
|
Kangmei Pharmaceutical Co Ltd
SHG:600518 |
Drug Manufacturers - Specialty & Generic | 0.00% |
|
Shanghai Haoyuan Chemexpress Co. Ltd. A
SHG:688131 |
Drug Manufacturers - Specialty & Generic | 1.37% |
|
Fujian Cosunter Pharmaceutical Co Ltd
SHE:300436 |
Drug Manufacturers - Specialty & Generic | -2.56% |
Annual Asset Resilience Ratio for Phapros Tbk PT (2011–2025)
The table below shows the annual Asset Resilience Ratio data for Phapros Tbk PT.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 5.08% | Rp70.40 Billion ≈ $4.13 Million |
Rp1.39 Trillion ≈ $81.28 Million |
+5.05pp |
| 2024-12-31 | 0.03% | Rp400.00 Million ≈ $23.44K |
Rp1.43 Trillion ≈ $83.79 Million |
-0.16pp |
| 2023-12-31 | 0.19% | Rp3.40 Billion ≈ $199.23K |
Rp1.77 Trillion ≈ $103.47 Million |
+4.47pp |
| 2022-12-31 | -4.28% | Rp-77.25 Billion ≈ $-4.53 Million |
Rp1.81 Trillion ≈ $105.84 Million |
-0.08pp |
| 2021-12-31 | -4.20% | Rp-77.15 Billion ≈ $-4.52 Million |
Rp1.84 Trillion ≈ $107.73 Million |
-2.84pp |
| 2020-12-31 | -1.36% | Rp-26.01 Billion ≈ $-1.52 Million |
Rp1.92 Trillion ≈ $112.27 Million |
-3.89pp |
| 2019-12-31 | 2.54% | Rp53.18 Billion ≈ $3.12 Million |
Rp2.10 Trillion ≈ $122.86 Million |
+2.64pp |
| 2018-12-31 | -0.11% | Rp-1.97 Billion ≈ $-115.14K |
Rp1.87 Trillion ≈ $109.50 Million |
-11.18pp |
| 2017-12-31 | 11.08% | Rp130.25 Billion ≈ $7.63 Million |
Rp1.18 Trillion ≈ $68.91 Million |
+11.66pp |
| 2013-12-31 | -0.59% | Rp-3.76 Billion ≈ $-220.58K |
Rp643.09 Billion ≈ $37.68 Million |
+0.07pp |
| 2012-12-31 | -0.66% | Rp-3.66 Billion ≈ $-214.69K |
Rp558.64 Billion ≈ $32.73 Million |
+0.19pp |
| 2011-12-31 | -0.84% | Rp-3.90 Billion ≈ $-228.29K |
Rp462.59 Billion ≈ $27.11 Million |
-- |
About Phapros Tbk PT
PT Phapros Tbk, together with its subsidiaries, operates in the pharmaceutical industry in Indonesia. The company operates through Ethical; Over the Counter (OTC) Drugs; Generic Drugs Bearing (OCB); and Toll-in segments. It offers OTC drugs, including Antimo Anak, Antimo tablet, Livron B Plex, Becefort Sirop and tablet, Noza, Febrinex, Betafort suspensi, and Hemorogard. The company also provides … Read more